Morgan Stanley analyst David Lewis attributes a recent 10% slide in shares of iRhythm (IRTC) to concerns about the Apple (AAPL) Heart Study, though he believes misperceptions around AHS may create a buying opportunity. Wall Street underappreciates the way the Apple Watch can expand the total addressable market and false positive rates "should dispel notions" that the Watch is a direct competitive threat to iRhythm, according to Lewis. Apple Watch creating a larger funnel of patients requiring a definitive diagnosis of presumptive AF "is a clear positive" for iRhythm's ZIO, added Lewis, who keeps an Overweight rating and $101 price target on iRhythm shares.

Alphabet (GOOGL), the parent company of Google, is scheduled to report first quarter 2024 results after the market close on Thursday, April 25, with a conference call scheduled for 4:30 pm Eastern Time. What to watch... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Apple saw sales of its iPhones fall 19.1% in the first three months of the year, CNBC's Ryan Browne reports, citing data from Counterpoint Research. Meanwhile, Huawei saw a 69.7% surge in smartphone sales in the country during the same period, Counterpoint said. Reference Link